


Technical Report No. 54-2

Implementation of Quality Risk Management for Pharmaceutical and Biotechnology Manufacturing Operations

Annex 1: Case Study Examples for Quality Risk Management in Packaging and Labeling

PCMOSM
Paradigm Change in
Manufacturing OperationsSM



2013



PDA Task Force on Technical Report No. 54-2: Implementation of Quality Risk Management for Pharmaceutical and Biotechnology Manufacturing Operations

Annex 1: Case Study Examples for Quality Risk Management in Packaging and Labeling

Authors

Ghada Haddad, MBA, Chair Genentech/Merck

Mike Boyson, Millennium: The Takeda Oncology Company

Boriana Cavicchia, URS

Mary Foster, PharmD, Aphenia Pharma Solutions

Mark Frankcom, YellowScape Consulting

Martin Hunter, Amgen

Bill Leung, Genentech

Liza Munda, Genentech

Mindy Pang, Merck

James Robinson, Lachman Consultants

David Thatcher, Amgen

PDA would like to acknowledge the contributions of **Jeffrey Hartman** (Merck) and **Christopher Smalley** (Merck), who served as PDA Advisory Board subject-matter advisors to this technical report team.

Disclaimer: This technical report annex was developed as part of PDA's Paradigm Change in Manufacturing Operations (PCMO) project. The content and views expressed in this Technical Report are the result of a consensus achieved by the Task Force and are not necessarily views of the organizations they represent.

Implementation of Quality Risk Management for Pharmaceutical and Biotechnology Manufacturing Operations

Annex 1: Case Study Examples for Quality Risk Management in Packaging and Labeling

Technical Report No. 54-2

ISBN: 978-0-939459-55-1

© 2013 Parenteral Drug Association, Inc.

All rights reserved.



Paradigm Change in Manufacturing Operations (PCMOSM)

PDA launched the project activities related to the PCMO program in December 2008 to help implement the scientific application of the ICH Q8, Q9 and Q10 series. The PDA Board of Directors approved this program in cooperation with the Regulatory Affairs and Quality Advisory Board, and the Biotechnology Advisory Board and Science Advisory Board of PDA.

Although there are a number of acceptable pathways to address this concept, the PCMO program follows and covers the drug product lifecycle, employing the strategic theme of process robustness within the framework of the manufacturing operations. This project focuses on Pharmaceutical Quality Systems as an enabler of Quality Risk Management and Knowledge Management.


Using the Parenteral Drug Association's (PDA) membership expertise, the goal of the Paradigm Change in Manufacturing Operations Project is to drive the establishment of 'best practice' documents and /or training events in order to assist pharmaceutical manufacturers of Investigational Medicinal Products (IMPs) and commercial products in implementing the ICH guidelines on Pharmaceutical Development (ICH Q8, Q11), Quality Risk Management (ICH Q9) and Pharmaceutical Quality Systems (ICH Q10).

The PCMO program facilitates communication among the experts from industry, university and regulators as well as experts from the respective ICH Expert Working Groups and Implementation Working Group. PCMO task force members also contribute to PDA conferences and workshops on the subject.

PCMO follows the product lifecycle concept and has the following strategic intent:

- Enable an innovative environment for continual improvement of products and systems
- Integrate science and technology into manufacturing practice
- Enhance manufacturing process robustness, risk based decision making and knowledge management
- Foster communication among industry and regulatory authorities

The Product Life Cycle



For more information, including the PCMO Dossier, and to get involved, go to www.pda.org/pcmo

Table of Contents

1.0 INTRODUCTION	1	4.7.2 Example 02—Translation Error	29
1.1 Purpose and Scope.....	1	4.7.2.1 Description of Error.....	29
2.0 GLOSSARY OF TERMS	3	4.7.2.2 Risk Assessment.....	29
3.0 CASE STUDY 1: CONTROL OF LIQUID DRUG PRODUCT DURING PACKAGING	5	4.7.2.3 Risk Control	29
3.1 Introduction.....	5	4.7.3 Example 03—Printer Assigns and Prints Label with Incorrect Barcode.....	30
3.2 QRM Planning.....	5	4.7.3.1 Description of Error.....	30
3.2.1 Team Selection	5	4.7.3.2 Risk Assessment.....	30
3.2.2 Process Description.....	5	4.7.3.3 Risk Control	30
3.2.3 Tool Selection	6	4.7.4 Risk Communication and Review	30
3.3 Risk Assessment	7	5.0 CASE STUDY 3: CONTROL OF LOGISTICS CHANNELS FOR LIQUID PRODUCT IN BULK HOLD PENDING PACKAGING	31
3.3.1 Risk Identification	7	5.1 Purpose and Scope.....	31
3.3.2 Risk Analysis	8	5.2 General Discussion of Application, Benefits, Considerations.....	31
3.3.3 Risk Evaluation	9	5.3 Process Step/Unit Operations.....	32
3.4 Risk Control	9	5.3.1 Brief Description of Process Step/Unit Operations	32
3.4.1 High Risks and Recommended Actions ..	10	5.3.2 Process Flowchart.....	32
3.4.2 Medium Risks and Recommended Actions	13	5.3.3 Identify Common Risks.....	32
3.5 Risk Communication.....	13	5.4 QRM Planning.....	34
3.6 Risk Review.....	13	5.4.1 Team Selection	34
4.0 CASE STUDY 2: RISKS ASSOCIATED WITH SECONDARY PACKAGING COMPONENTS PRODUCTION	20	5.4.2 Tool Selection	34
4.1 Introduction.....	20	5.4.3 Process Description.....	34
4.2 QRM Planning.....	20	5.5 Risk Assessment.....	35
4.2.1 Team Selection	20	5.5.1 Risk Identification	35
4.2.2 Tool Selection	20	5.5.2 Risk Analysis and Evaluation	36
4.2.3 Process Description.....	20	5.6 Risk Control: Risk Reduction, Risk Acceptance	38
4.2.3.1 Secondary Packaging Components Production Process Flow	21	5.7 Risk Communication.....	39
4.3 Risk Assessment.....	23	5.8 Risk Review.....	39
4.3.1 Risk Identification	23	6.0 CASE STUDY 4: RISKS IN PACKAGING, HANDLING AND TRANSPORT OF LIQUID FILLED GLASS SYRINGE	40
4.3.2 Risk Analysis	23	6.1 Introduction	40
4.3.3 Risk Evaluation	24	6.2 QRM Planning.....	40
4.4 Risk Control	28	6.2.1 Product and Process Description.....	40
4.4.1 Risks and Recommended Actions	28	6.2.2 Tool Selection	42
4.5 Risk Communication.....	28	6.2.2.1 Definitions of FTA Symbols.....	42
4.6 Risk Review.....	28	6.2.2.2 Benefits of FTA	42
4.7 Additional Examples of Potential Failure Modes Arising from Process Substep Risks.....	28	6.2.3 Team Selection	42
4.7.1 Example 01—Dosing Artwork Error	28	6.3 Risk Overview	43
4.7.1.1 Description of Error.....	28	6.4 Risk Control Effectiveness Monitoring.....	45
4.7.1.2 Risk Assessment.....	29	6.5 Fault Tree Analysis	45
4.7.1.3 Risk Control	29		

7.0 CASE STUDY 5: CONTROL OF LOGISTICS CHANNELS FOR REFRIGERATED BULK SOLID ORAL DOSE	46
7.1 Introduction.....	46
7.2 Prerequisites: Planning, Team Selection, Product Analysis	46
7.3 Risk Assessment Scope and Methodology ...	47
7.4 Risk Identification.....	47
7.5 Risk Analysis.....	49
7.6 Risk Evaluation.....	50
7.7 Risk Communication.....	51
7.8 Risk Review.....	51

8.0 CONCLUSION	52
9.0 ADDITIONAL READING	53
10.0 REFERENCES	54

FIGURES AND TABLES INDEX

Figure 3.2.2-1 Process Flow Diagram for Bottling and Packaging a Liquid Product.....	6	Figure 5.3.3-2 Absorbent Pad and Plastic Bag.....	33
Table 3.3.1-1 Type of Hazard and Harm by Process Step	7	Figure 5.4.3-1 Shipping Lane.....	34
Table 3.3.2-1 Severity Scoring	8	Figure 5.5.1-1 Process Map	35
Table 3.3.2-2 Likelihood of Occurrence Scoring	8	Table 5.5.2-1 Risk Evaluation and Acceptability Decision.....	36
Table 3.3.3-1 Risk Matrix	9	Table 5.5.2-2 Examples of FMEA Ratings	37
Table 3.3.3-2 Risk Acceptability Decision	9	Table 6.2.1-1 Product Conditions and Requirements	41
Table 3.4.1-1 High Risks	11	Figure 6.2.1-1 Process Steps	41
Table 3.6-1 Risk Assessment Table.....	14	Table 6.3-1 Risks and Recommended Actions	44
Figure 4.2.3.1-1 Secondary Packaging Components Production Process Flow	21	Figure 6.5-1 Case Study Fault Tree Analysis	45
Table 4.3.2-1 Risk Scoring Definitions	23	Table 7.2-1 Product In-transit Specifications.....	46
Table 4.3.3-1 Risk Priority Matrix.....	24	Figure 7.3-1 Shipping Lane Overview	47
Table 4.3.3-2 Risk Assessment Table	25	Table 7.4-1 Hazards Identified	48
Figure 5.3.2-1 Packing: Passive System.....	32	Table 7.5-1 Risk Scores	49
Figure 5.3.3-1 Bubble Wrap and Cold Packs.....	33	Figure 7.5-1 Threat Map of Categorized Risks.....	49
		Table 7.6.1-1 High Risks and Recommended Actions..	50

1.0 Introduction

Quality Risk Management (QRM) is a systematic process for the assessment, control, communication, and review of risks. It is a mechanism of ensuring product quality is maintained throughout the product lifecycle.

An effective QRM program ensures high quality of drug product to the patient. QRM can be applied both proactively and retrospectively and should ensure that:

- the evaluation of the risk to quality is based on scientific knowledge, experience with the process, and ultimately links to the protection of the patient;
- the level of effort, formality and documentation of the quality risk management process is commensurate with the level of risk.

QRM should include systemic processes designed to coordinate, facilitate, and improve science-based decision making with respect to risk. Since the basis of any usable risk assessment is scientific knowledge and experience with the process being assessed, the evaluation of identified and analyzed risks should be defined by the risk to product quality and patient safety. Furthermore, there should be evidence for effectiveness of risk control, appropriate rationale where residual risk elements are accepted, and clear evidence that supports the decisions made.

To apply the principles of QRM, it is not always necessary or appropriate to use a formal risk assessment tool (e.g., PHA, FMEA, FTA): the use of informal risk management tools is acceptable for areas of less complexity and lower potential risk. The decision of formality in documentation should be based on each company's risk management program. The complexity of the events surrounding each decision and the potential risk involved are important inputs in determining the appropriate risk assessment methodology and corresponding level of analysis required to ensure the appropriate risk decision is made.

For the less complex and/or those decisions involving little risk, a qualitative analysis (e.g., decision tree) of the options may be all that is required. Generally, as the complexity and/or risk increases, so should the sophistication of the risk assessment tool used to facilitate the corresponding analysis.

When performing risk assessments, it is vital to use a cross-functional team so that all aspects of the process are adequately evaluated. Another critical component of this effort is to identify the key experts in the team, those who are knowledgeable in risk management principles and possess a specific set of skills in order to facilitate and lead the risk assessment sessions.

1.1 Purpose and Scope

PDA *Technical Report No. 54-2* is a supplemental annex to PDA *Technical Report No. 54: Implementation of Quality Risk Management for Pharmaceutical and Biotechnology Manufacturing Operations (1)*. The technical report was distributed for peer review for comment prior to publication to ensure its suitability as a valuable guide for QRM implementation in packaging and labeling operations.

In this document, specific case studies on how to apply quality risk management (QRM) to pharmaceutical manufacturing, specifically packaging and labeling operations, are presented. Each case study highlights the different applications of QRM throughout the pharmaceutical and biotechnology manufacturing operations in packaging and labeling.

The various risk-scoring criteria in this document serve to emphasize the many uses of QRM across the industry when implementing the ICH Q9 guideline (2). They also are a reminder that there is no "one way" of using QRM.

The illustrated examples highlighted in this document of how to apply QRM tools to the packaging and labeling of products are solely based on the opinion and experience of subject-matter experts

(SMEs) who served on the authoring Task Force. Therefore, the content in this report does not represent the QRM practices of any one particular organization, because every organization may have unique elements to its QRM program.

NOTE: To further demonstrate the different approaches companies may employ, each case study is organized differently, though they share similar elements.

This report is intended to align with ICH Q9 and is one in a series of similar documents that provide additional examples of how to apply risk management tools across the product supply chain, from the starting materials (APIs and excipients) through manufacturing, labeling, packaging, and shipping.